Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00247611 · ClinicalTrials.gov registry record · Phase 2

Improving Treatment Adherence in HIV-Infected Individuals

A Phase 2 study, sponsored by University of Connecticut.

Completed
Registry status
Phase 2
Development phase
594
Enrollment target

NCT00247611: Completed Phase 2 study, sponsored by University of Connecticut.

NCT00247611 is a Phase 2 study that has completed, run by University of Connecticut. The registered enrollment target is 594 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (347% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00247611, a Phase 2 study, has completed, sponsored by University of Connecticut.

COMPLETED
Registry status
Phase 2
Development phase
594 participants
Enrollment target

Study Summary

This study will develop and evaluate the efficacy of an individualized, interactive, computer software program delivered in conjunction with clinical care in increasing and supporting antiretroviral therapy adherence in HIV-infected individuals.

Primary Outcome

This measure asks participants to report the number of doses taken on each of the past 3-days, relative to number he or she was prescribed to take, and produces a % adherence score. For this study, adherence over the past 3-days was established for each medication separately then averaged over the full regimen. For main outcomes, perfect vs imperfect adherence was evaluated. Significant findings on perfect/imperfect adherence were followed with sensitivity tests to determine if lowest threshold

Interventions

  • OTHER Control
  • BEHAVIORAL LifeWindows Intervention Sessions

Trial Details

FieldValue
Enrollment Target 594 participants
Start Date 2005-10
Est. Completion 2008-03
Phase Phase 2
University of Connecticut

107 total trials

What the finished NCT00247611 record still lists

NCT00247611 is an interventional study that assigns participants to a tested intervention. The registered 594 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (347% higher).

The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.

NCT00247611 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00247611 about?

NCT00247611 is a clinical study titled "Improving Treatment Adherence in HIV-Infected Individuals". This study will develop and evaluate the efficacy of an individualized, interactive, computer software program delivered in conjunction with clinical care in increasing and supporting antiretroviral therapy adherence in HIV-infected individuals.

What is the current status of trial NCT00247611?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 594 participants. The study started on 2005-10. Estimated completion is 2008-03.

What interventions are being tested in trial NCT00247611?

The interventions under investigation include: Control (OTHER), LifeWindows Intervention Sessions (BEHAVIORAL).

Who is sponsoring clinical trial NCT00247611?

This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00247611's enrollment target sits among peer trials

594 57th of 2000 higher than 1,943 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04701684 · 594 participants · NA

    WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

  • NCT05491213 · 594 participants · NA

    TELESCOPE- TELEhealth Shared Decision-making COaching

  • NCT05867420 · 594 participants · Phase 1

    A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

  • NCT06890884 · 594 participants · Phase 2

    A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00247611, the US trial registry maintained by the National Library of Medicine. NCT00247611 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.